Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Orchard Therapeutics PLC Sponsored ADR (ORTX : NSDQ)
 
 • Company Description   
Orchard Therapeutics plc is a biopharmaceutical company. It offers medical research, gene therapy and inherited disorder treatment services which transforms the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Orchard Therapeutics plc is based in London, United Kingdom.

Number of Employees: 259

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.47 Daily Weekly Monthly
20 Day Moving Average: 631,625 shares
Shares Outstanding: 125.90 (millions)
Market Capitalization: $58.96 (millions)
Beta: 1.20
52 Week High: $5.69
52 Week Low: $0.41
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -29.65% -22.92%
12 Week -52.51% -48.48%
Year To Date -64.52% -57.81%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
108 CANNON STREET
-
LONDON,X0 EC4N 6EU
GBR
ph: 011-44-0-203-3846700
fax: -
None http://www.orchard-tx.com
 
 • General Corporate Information   
Officers
Bobby Gaspar - Chief Executive Officer and Director
James A. Geraghty - Chairman of the Board of Directors
Frank E. Thomas - President and Chief Operating Officer
Joanne T. Beck - Director
John Curnutte - Director

Peer Information
Orchard Therapeutics PLC Sponsored ADR (CORR.)
Orchard Therapeutics PLC Sponsored ADR (RSPI)
Orchard Therapeutics PLC Sponsored ADR (CGXP)
Orchard Therapeutics PLC Sponsored ADR (BGEN)
Orchard Therapeutics PLC Sponsored ADR (GTBP)
Orchard Therapeutics PLC Sponsored ADR (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 68570P101
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding: 125.90
Most Recent Split Date: (:1)
Beta: 1.20
Market Capitalization: $58.96 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.25 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.94 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.34
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -12.90%
vs. Previous Quarter: -20.69%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 1,043.69%
ROE
03/31/22 - -68.98
12/31/21 - -57.19
09/30/21 - -57.92
ROA
03/31/22 - -46.08
12/31/21 - -40.39
09/30/21 - -40.81
Current Ratio
03/31/22 - 5.06
12/31/21 - 6.43
09/30/21 - 6.59
Quick Ratio
03/31/22 - 5.06
12/31/21 - 6.43
09/30/21 - 6.59
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -2,137.78
12/31/21 - -8,582.45
09/30/21 - -11,834.48
Book Value
03/31/22 - 1.40
12/31/21 - 1.67
09/30/21 - 1.92
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.17
12/31/21 - 0.15
09/30/21 - 0.14
Debt-to-Capital
03/31/22 - 14.51
12/31/21 - 13.26
09/30/21 - 11.96
 

Powered by Zacks Investment Research ©